Sitagliptin therapy significantly reduced fasting plasma triglyceride ( -15.4 % , p = 0.03 ) , apoB-48 ( -16.3 % , p = 0.03 ) and free fatty acid concentrations ( -9.5 % , p = 0.04 ) , as well as plasma HbA1c ( placebo : 7.0 % 0.8 vs. sitagliptin : 6.6 % 0.7 , p < 0.0001 ) and plasma glucose levels ( -13.5 % , p = 0.001 ) , without any significant effect on insulin levels .